Kanavit

Phytomenadione, the active ingredient in Kanavit, is a Vitamin K presented as an oral formulation for oral use. It is employed to correct vitamin K deficiency, manage bleeding episodes, and reverse the effects of vitamin K antagonist anticoagulants in patients requiring rapid coagulation restoration.

GNH USA supplies Kanavit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Kanavit is a vitamin K agent used to address disorders of coagulation and to counteract anticoagulant therapy. - Vitamin K deficiency: restores normal clotting factors in patients with low vitamin K levels. - Hemorrhage prevention and treatment: supports hemostasis in acute bleeding situations. - Warfarin reversal: rapidly re‑establishes coagulation in individuals receiving vitamin K antagonist anticoagulants.

Adverse reactions may occur with oral vitamin K therapy.

Common Side Effects: - Nausea: mild gastrointestinal discomfort. - Diarrhea: loose stools occurring shortly after ingestion. - Headache: transient cranial pain. - Skin rash: mild erythematous eruption. - Elevated liver enzymes: mild, reversible increase.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hemolytic anemia: rare destruction of red blood cells. - Thromboembolic events: unexpected clot formation. - Hyperbilirubinemia: elevated bilirubin levels in susceptible individuals. - Severe hypersensitivity: swelling of face, lips, or throat.

When prescribing Kanavit, clinicians should consider several safety measures. - Dose adjustment in liver disease: impaired metabolism may require lower doses. - Monitor INR in patients on anticoagulants: ensure therapeutic coagulation levels. - Avoid in known hypersensitivity: discontinue if allergic reactions develop. - Use with caution in newborns: vitamin K status is critical in this population. - Store at room temperature: keep in the original pack, protect from moisture.

Kanavit can interact with several medications that affect coagulation or vitamin K metabolism.

Major Interactions (Avoid): - Warfarin: may reduce anticoagulant effect, leading to sub‑therapeutic INR. - Broad‑spectrum antibiotics (e.g., ampicillin‑clavulanate): can diminish intestinal vitamin K synthesis.

Moderate Interactions (Monitor Closely): - Cefoperazone or ceftriaxone: may alter vitamin K levels and affect clotting. - Barbiturates: increase hepatic metabolism of vitamin K. - Oral contraceptives: may enhance clotting tendency, requiring monitoring.